关键信息
-
基因名
LILRA4/ILT-7/CD85g
-
简介
The LILRA4/ILT-7/CD85g protein is a coreceptor that critically limits the innate immune response during viral infection through FCER1G signaling. It negatively regulates TLR7 and TLR9 signaling and reduces IFNA1, IFNA2, IFNA4, IFNB1, and TNF production in dendritic cells exposed to influenza virus or CpG dinucleotides. LILRA4/ILT-7/CD85g Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived LILRA4/ILT-7/CD85g protein, expressed by HEK293 , with C-His labeled tag.
- 应用
-
别名
CD85g; ILT7; ILT-7; ILT7MGC129598; LILRA4; MGC129597
-
种属
Cynomolgus
-
表达系统
HEK293
-
标签
C-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
XP_005590346
-
表达区间
E24-N446
-
蛋白长度
Partial
-
分子量
60-70 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
LILRA4, also known as ILT-7 or CD85g, is a member of the leukocyte immunoglobulin-like receptor (LILR) family, which plays a crucial role in immune regulation. The protein is predominantly expressed on plasmacytoid dendritic cells (pDCs) and is involved in mediating the immune response to viral infections and autoimmune diseases. Research on LILRA4 has gained traction due to its alternative splicing variants that can function as either activating or inhibitory receptors, thus contributing to a nuanced understanding of immune signaling pathways. LILRA4 interacts with various ligands, including MHC class I molecules, which modulates the activation of immune cells. The study of LILRA4 as a recombinant protein holds significant potential for therapeutic applications, particularly in the context of enhancing antiviral immunity or dampening excessive immune responses in autoimmune disorders. Understanding the structure and function of this receptor can also facilitate the development of novel immunotherapeutic strategies aimed at targeting pDCs and their role in immunopathology. Given its pivotal function in balancing immune responses, LILRA4 is a promising target for research focused on designing targeted therapies that improve outcomes in infectious and autoimmune diseases.
